Watson finds itself shut out of generic Actos launch
Deborah Weinstein
August 20 2012
Ranbaxy and Teva each launched authorized generic versions of Actos, but Watson may lose its share in the 180-day period ...
Your Email Address: *
Recipient(s) Email Address: *
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
Your message:
The e-mail address(es) that you supply to use this service will only be used to send the requested article.